The poor outcome of cancer gene therapy in clinical trials relates in part to insufficient gene delivery to tumor sites. Mesenchymal stem cells (MSCs) represent a new tool for the delivery of therapeutic agents to tumor cells. This study used an orthotopic nude mice model of hepatocellular carcinoma (HCC) to evaluate the potential of genetically modified human MSCs (hMSCs), to function as an effective delivery vehicle for therapeutic genes. hMSCs derived from the bone marrow were efficiently engineered to express human pigment epithelium-derived factor (PEDF) by lentiviral transduction, then tested in vitro for high-level expression and bioactivity of the transgenic protein. The preferential homing of hMSCs toward HCC was confirmed by in vitro and in vivo migration assays. in vivo efficacy experiments showed that intravenous (i.v.) injection of PEDF-expressing hMSCs significantly suppressed both the growth of primary liver tumors and the development of pulmonary metastases. Moreover, hMSCs-based PEDF gene delivery moderately increased the systemic levels of human PEDF. Immunohistochemistry of primary liver tumors demonstrated lower microvessel density in mice treated with hMSCs-PEDF than in control mice. This is the first study to show the potential of hMSCs as an effective delivery vehicle for therapeutic genes in the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequently diagnosed cancer and the third most common cause of cancer mortality worldwide (Lau and Lai, 2008) . Hepatic resection and liver transplantation are the primary treatments for HCC. Unfortunately, at the time of clinical presentation, the disease is often too advanced for the patient to benefit from resection. Furthermore, access to liver transplantation is limited because of a shortage of donor organs. In patients who do undergo surgical treatment, there is a high incidence of recurrence, thus limiting the long-term effectiveness of these procedures (Chang et al., 2007; Mittler et al., 2008) . Therefore, there is an urgent need for novel and effective therapeutic strategies for the treatment of HCC.
Cancer gene therapy is clinically the most active field in gene therapy, and the most promising. Although previous studies have yielded some exciting results in animal models, clinical trials have shown limited antitumor efficacy due in part to insufficient gene delivery to tumor sites (Komarova et al., 2006) . Introduction of a transgene of interest into mesenchymal stem cells (MSCs) poses an attractive cell-based delivery strategy (Studeny et al., 2002; Fritz and Jorgensen, 2008) . The rationale for using bone marrowderived MSCs for delivering therapeutic agents to tumors is based on the concept that the bone marrow is a source of circulating MSCs that are recruited from the blood into peripheral solid organs in times of tissue stress or injury. As the microenvironment of a solid tumor is similar to that of an injured tissue, solid tumors may provide a permissive environment for the engraftment of exogenously given MSCs (Nakamizo et al., 2005; Kidd et al., 2009) . The clinical use of bone marrow-derived MSCs is attractive for a number of reasons: they are easy to transduce with viral vectors, they can be easily harvested, isolated and expanded and they have low immunogenicity (Ren et al., 2008a) .
Various vectors are available to transduce genes into MSCs, including retroviral, adenoviral and lentiviral vectors (Kanehira et al., 2007) . Adenoviral vectors are the most common vectors currently available with high titers. However, the transduction efficiency of MSCs by conventional adenoviral vectors has been shown to be only up to 20% because of the low expression of coxsackie-adenoviral receptors in MSCs (Mizuguchi et al., 2005) . The inability of retroviral vectors to transduce nondividing cells also limits their clinical application. Lentiviral vectors have the ability to transduce both dividing and nondividing cells, as well as to stably integrate into the genome of target cells, which guarantees long-term expression of therapeutic genes (Van Damme et al., 2006) . These advantages justify the use of lentiviral vectors for transducing human MSCs (hMSCs) in this study. Angiogenesis, the process by which new blood vessels develop from preexisting blood vessels, is an essential step that enables tumors to gain their own sustainable blood supply, therefore supporting further growth and metastasis (Chen et al., 2001; Persano et al., 2007) . Hence, angiogenesis inhibitors, targeting either the neovasculature or the signals that promote new vessel growth should be a promising approach in the treatment of HCC, now that it is known to be one of the most vascular solid tumors (Yang and Poon, 2008) . Pigment epithelial-derived factor (PEDF) is a 50-kDa secreted glycoprotein, which was initially identified as a neurotrophic factor (Tombran-Tink and Johnson, 1989) . It was later discovered that PEDF has potent antiangiogenic activity, far greater than any other known endogenously produced inhibitors of angiogenesis, including angiostatin, endostatin and thrombospondin-1 (Dawson et al., 1999) . Studies have already shown that low intratumoral expression of PEDF is associated with a higher microvessel density, a more metastatic phenotype and poorer prognosis in prostate cancer, pancreatic cancer, breast cancer and gliomas (Guan et al., 2003; Halin et al., 2004; Uehara et al., 2004; Cai et al., 2006) . PEDF seems to exert its antitumor activity through multiple mechanisms. Studies have shown widespread activities against tumor proliferation, cellular invasion, migration, differentiation and tumor angiogenesis (Garcia et al., 2004; Filleur et al., 2005; Streck et al., 2005; Ek et al., 2007) . Matsumoto et al. (2004) reported that the serum concentration of PEDF was decreased in patients with cirrhosis or HCC complicated by cirrhosis compared with healthy volunteers, which indicated the role of PEDF in the progress of HCC.
In this study, hMSCs derived from the bone marrow were efficiently engineered to secrete human PEDF by lentiviral transduction, and these cells demonstrated their ability to preferentially migrate toward HCC both in vitro and in vivo. In addition, a significant antitumor effect of PEDF-expressing hMSCs was observed in this orthotopic nude mouse model of HCC after intravenous (i.v.) administration, which correlated with the downregulation of tumoral neoangiogenesis.
Results

Characteristics of hMSCs and lentiviral transduction
Human bone marrow MSCs have a typical spindle shape, consistent with the morphology reported by others (Pittenger et al., 1999; Nakamizo et al., 2005) . Although hMSCs do not have a specific antigen profile for each culture, it was verified that isolated cells were negative for typical hematopoietic antigens CD45, CD34 and CD14 and were positive for CD105, CD29 and CD90 (Figure 1a) . Thus, on the basis of the available criteria, the cells used in these experiments had the properties of hMSCs, as described previously (Nakamizo et al., 2005; Sotiropoulou et al., 2006; Bernardo et al., 2007) .
To test the utility of lentiviral vectors for gene transfer to hMSCs, hMSCs were infected with LV-PEDF or LVgreen fluorescence protein (GFP), and the transduction efficiency of recombinant lentivirus was examined by fluorescence-activated cell-sorting analysis. Forty-eight hours after transduction, 96.38% of cells were GFP positive (Figures 1b and c) .
High-level expression and bioactivity of PEDF produced by PEDF-transduced hMSCs in vitro To determine whether PEDF could be secreted in lentivirus-infected hMSCs, western blot using a monoclonal antibody against human PEDF was used to analyze the conditioned media (CM) as well as lysates from hMSCs-PEDF, hMSCs-GFP and untransduced hMSCs. As shown in Figure 2a , a specific M r 50 000 band was observed only in the CM and lysates from LV-PEDF-transduced cells, which indicated that PEDF was appropriately synthesized and processed. ELISA (enzyme-linked immunosorbent assay) showed that hMSCs-PEDF cells had secreted PEDF into the culture medium at a concentration of 125.6 ng/ml, whereas only minimal PEDF was detected in the CM obtained from untransduced and LV-GFP-transduced hMSCs ( Figure 2b) .
Assays of in vitro tube formation using human umbilical vein endothelial cells confirmed the lentivirus-mediated expression of biologically active PEDF. When human umbilical vein endothelial cells are cultured on Matrigel, they rapidly align and form hollow tube-like structures (Haralabopoulos et al., 1994) . The CM derived from hMSCs-GFP did not affect tube formation. However, there were significant decreases in tube formation in the group treated with the CM derived from hMSCs-PEDF (Figure 2c ).
Migratory capacity of hMSCs toward HCC in vitro
In several reports, MSCs have been shown to migrate to melanoma, breast carcinoma, Kaposi's sarcoma, colon carcinoma, glioma and prostate cancer (Studeny et al., 2004; Nakamizo et al., 2005; Khakoo et al., 2006; Dwyer et al., 2007; Ren et al., 2008b) . To test whether hMSCs have the ability to migrate toward hepatocarcinoma cells, an in vitro transwell migration assay was performed. In this experiment, the CM derived from the normal human hepatic cell line L02 was used as a control to better mimic the normal liver milieu. As shown in Figures 3a and b , only a few hMSCs migrated toward the CM collected from L02 cells, whereas the number of hMSCs that migrated toward the CM collected from MHCC-97H or HepG2 cells was significantly higher (*Po0.001). It was also confirmed that hMSCs-PEDF migrated toward the CM collected from hepatocarcinoma cells in a similar manner to untransduced hMSCs (data not shown). These results strongly suggested that human hepatocarcinoma cells were capable of stimulating the migration of hMSCs and that the migratory ability of hMSCs was not affected by lentiviral transduction.
Migratory capacity of hMSCs toward HCC in vivo
To determine whether hMSCs are capable of selectively migrating toward tumor microenvironment after systemic delivery in vivo, intrahepatic MHCC-97H-GFP xenografts were established in the left liver lobes of nude mice as described previously . Ten days after tumor inoculation, CM-DiI-labeled hMSCs (10 6 suspended in 200 ml of phosphate-buffered saline (PBS)) were i.v. injected into mice (n ¼ 8). At day 7 after tail vein injection, the majority of hMSCs traversed vessels and migrated toward the tumor mass ( Figure 4a ). CM-DiI-labeled hMSCs were localized mainly around the edge of the primary liver tumors (Figure 4b) , although a few hMSCs were also observed in the lungs of tumor-bearing mice (Figure 4c ). By 14 days after injection, most of the hMSCs had infiltrated into the tumor bed and were distributed extensively throughout the tumor mass (Figure 4d ), whereas they were undetectable in the lungs. No other examined organs (such as the spleen, heart, brain, pancreas or kidneys) showed signs of CM-DiI-labeled hMSCs engraftment at either 7 or 14 days after injection (data not shown).
Next, an investigation was conducted to determine whether hMSCs could localize to HCC tumors other than MHCC-97H xenografts. Intrahepatic tumors were established in the left liver lobes of nude mice (n ¼ 5) using the HepG2 cell line as described above. Fourteen days after injection into the tail vein, CM-DiI-labeled hMSCs were identified within the HepG2 xenografts (Figure 4e ), suggesting that the ability of hMSCs to 
Therapeutic effects of hMSCs-PEDF on HCC in vivo
To evaluate the efficacy of systemic application of hMSCs-PEDF in suppressing the progress of HCC in vivo, 12 randomly selected mice from each group were killed and autopsied at day 35 after treatment. The average size of primary liver tumors in control mice that received PBS was 1467.2 ± 312.4 mm 3 . As shown in Figure 5a , the tumor volume in mice that received i.v. injection of hMSCs-PEDF was dramatically smaller compared with that of control mice (353.5 ± 86.6 mm (c) Antiangiogenic activity of PEDF in the CM was assessed by in vitro tube formation of human umbilical vein endothelial cells. Top: tube formation was blocked by PEDF produced by PEDF-engineered hMSCs (magnification, Â 100). Below: tube formations were quantified by counting the tubes in five randomly selected fields (magnification, Â 50). Significantly fewer tubes were seen per view in the group treated with the CM derived from hMSCs-PEDF as compared with the group treated with the CM derived from untransduced hMSCs or hMSCs-GFP (*Po0.001, two-tailed Mann-Whitney U-test). *Po0.001). In contrast, the growth rate of primary tumors was not affected by administration of recombinant LV-PEDF (1377.1 ± 297.1 mm 3 , P40.05). Similarly, the mean volume of tumors from mice treated with hMSCs-GFP was also not statistically different from that of control mice (1403.5±316.2 mm 3 , P40.05). Figure 5b shows representative photographs of the livers with implanted HCC tumors 35 days after treatment. These findings suggest that i.v. administration of hMSCs-PEDF inhibits the growth of primary liver tumors, whereas i.v. injected recombinant LV-PEDF or hMSCs-GFP does not.
The efficacy of hMSCs-PEDF treatment for the prevention of spontaneous pulmonary metastases was also evaluated. In this model, micrometastatic foci in the lungs, identified on hematoxylin and eosin-stained slides, were observed 35 days after orthotopic transplantation of MHCC-97H tumors ( Figure 5c ). As shown in Figure 5d , the number of micrometastatic foci in the lungs of control mice was 18.9 ± 3.4. Pulmonary metastases were not affected by administration of hMSCs-GFP (20.8±3.3) or by LV-PEDF (19.4±3.5). In contrast, systemic administration of hMSCs-PEDF significantly suppressed pulmonary metastases of HCC in vivo. The number of micrometastatic foci in the group treated with hMSCs-PEDF was 1.8 ± 2.2, and in this group, five mice did not develop pulmonary metastases.
The remaining mice (n ¼ 10 for each group) were followed up until death to determine whether hMSCs-PEDF treatment improved the survival of tumorbearing mice. As shown in Figure 6 , mice treated with hMSCs-PEDF lived statistically significantly longer than did control mice (median survival: 99 versus 57 days, *Po0.001), whereas mice treated with hMSCs-GFP (median survival: 61 days, P ¼ 0.958) or LV-PEDF (median survival: 63 days, P ¼ 0.174) did not.
PEDF-expressing hMSCs therapy inhibited tumor angiogenesis in vivo HCC is one of the most vascular solid tumors. Angiogenesis has an important role in its development, progression and metastasis (Yang and Poon, 2008) . As PEDF is a potent inhibitor of angiogenesis, the study sought to determine whether delivery of hMSCs-PEDF reduces intratumoral angiogenesis. This was carried out with immunohistochemical analysis using an antibody against CD34, which is expressed on microvessel endothelial cells. As shown in Figures 7a and b , tumors from mice treated with PBS, hMSCs-GFP or LV-PEDF showed intense staining for CD34, indicating the presence of extensive angiogenesis in the tumors, whereas microvessel density in tumors from mice treated with hMSCs-PEDF was markedly lower.
Serum levels of human PEDF after therapy PEDF is a molecule that is widely expressed throughout the body; therefore, it seems unlikely that its therapeutic administration elicits major toxic effects in the body. However, PEDF therapy ideally should be targeted to the tumor tissue so that no undesired side effects such as perturbation of angiogenesis involved in the menstrual cycle or wound healing are invoked. To obtain information regarding the systemic levels of PEDF in mice after treatment, serum samples were collected on days 7, 14, 21, 28 and 35 after therapy, and the Figure 4 Migration of hMSCs toward hepatocellular carcinoma in vivo. MHCC-97H cells were stably transduced with LV-GFP and appeared green under fluorescent microscopy. (a) At day 7 after tail vein injection, the majority of hMSCs traversed vessels and migrated toward the tumor mass (magnification, Â 100). (b) CM-DiI-labeled hMSCs (red) were localized mainly around the edge of the primary liver tumors 7 days after hMSCs were injected i.v. (magnification, Â 100). (c) A few hMSCs were also detected in the lungs of tumor-bearing mice 7 days after tail vein injection (magnification, Â 100). (d) At day 14 after hMSCs administration, hMSCs mostly infiltrated into the tumor bed and were distributed extensively throughout the tumor mass (magnification, Â 100). (e) Photomicrograph of liver sections showing selectivity of hMSCs engraftment for HepG2 xenograft. Sections were also stained with fluorescence-conjugated antibody (4 0 ,6-diamidino-2-phenylindole (DAPI)). Fourteen days after i.v. administration, CM-DiI-labeled hMSCs were identified within the HepG2 xenografts. Top: low-power view (magnification, Â 50) of the section; bottom: high-power view (magnification, Â 200) of the section. T, tumor area; L, the healthy liver.
Discussion
MSCs represent an attractive option as a delivery vehicle for therapeutic genes. This has been attributed to the apparent ability of MSCs to both migrate to tumor sites and to evade host immune response (Fritz and Jorgensen, 2008) . In this study, the migration of hMSCs in vitro was stimulated by the CM from cultured MHCC-97H and HepG2 cells. Although MHCC-97H and hepG2 are genetically and phenotypically distinct hepatocarcinoma cell lines, selective engraftment of hMSCs into tumor mass was observed in both xenografts in vivo. It has been shown that epidermal growth factor, platelet-derived growth factor, stromal cell-derived factor-1 and monocyte chemotactic protein-1 may have a role in the intrinsic tumor-specific migration capacity of hMSCs (Nakamizo et al., 2005; Dwyer et al., 2007; Fritz and Jorgensen, 2008) . Despite these promising results, the migratory properties of hMSCs need to be further evaluated for tumor-type specificity and for the possible signaling molecules that are involved, before translation into clinical practice can occur.
In a previous study, Nakamizo et al. (2005) reported that majority of hMSCs were filtered by the lung, and few cells were detected in the intracranial glioma of nude mice after i.v. administration. In the current study, 7 days after i.v. administration, a few hMSCs were observed in the lungs, whereas 14 days after i.v. administration, these cells were undetectable in the lungs and were distributed extensively throughout the tumor mass. It is possible that, owing to their relatively large size and strong adhesive properties, hMSCs may be trapped by the capillary network and retained in the lungs for several days before they recirculate and localize to tumor sites. Therefore, in the aforementioned nude mice model of intracranial glioma, 7 days would not have been long enough to detect the eventual distribution of administered hMSCs. The tumor-tracking properties of i.v. administered hMSCs have also been demonstrated in some subcutaneous tumor models (Studeny et al., 2002; Hung et al., 2005) . The results obtained from this orthotopic model of HCC further strengthen the argument that hMSCs can target and engraft into tumor mass after i.v. administration.
In this study, hMSCs were efficiently engineered to express human PEDF through lentiviral transduction. It was shown that the CM derived from these engineered hMSCs was capable of inhibiting the tube formation of human umbilical vein endothelial cells in vitro. Most importantly, i.v. injection of PEDF-engineered hMSCs significantly suppressed tumor growth and development of metastases, and prolonged the survival in mice with preestablished intrahepatic MHCC-97H xenografts. The MSCs-based delivery of PEDF was clearly superior to the reported plasmid-based, nonviral gene transfer method (Matsumoto et al., 2004) . PEDF overexpression was not seen at day 11 after the third intratumoral injection of PEDF-expressing plasmid in that study, and tumors started to escape growth suppression, whereas PEDF expression sustained at least for 35 days in vivo after hMSCs-PEDF therapy in this study. In addition, i.v. delivery of hMSCs obviates invasive surgical interventions and makes repeated injections clinically feasible. Despite the observed dramatic antitumor effects, systemic serum PEDF levels were moderately higher in mice treated with hMSCs-PEDF. Direct injection of recombinant LV-PEDF had no effect on the growth of primary liver tumors and the development of pulmonary metastases, although the serum PEDF levels were much higher in this group than in the hMSCs-PEDF-treated mice. Systemically administered viral vectors are distributed widely throughout the whole body, and there is a physical barrier between blood and tumor cells in preestablished tumors (Yoon et al., 2001 ). Therefore, it is possible that the dose of recombinant LV-PEDF delivered in this experiment is less than the effective concentration. Study results suggest that the antitumor activity of hMSCs-PEDF is associated not with the serum concentration of PEDF but rather with the engraftment of hMSCs in tumors and with the local effects of PEDF they produce on HCC.
This study shows, for the first time, the tropism of hMSCs derived from the bone marrow for HCC. hMSCs can be genetically modified ex vivo to express genes that have therapeutic efficacy against HCC. These results suggest a potential role of hMSCs as a targeted, therapeutic delivery vehicle for the treatment of HCC. Although this study indicates that PEDF is itself a good therapeutic agent worthy of assessment in patients with HCC, the same approach can be also exploited to deliver other agents with antitumor activity.
Materials and methods
Cell lines and animals
Human hepatocarcinoma cell lines MHCC-97H and HepG2, human normal hepatic cell line L02, human umbilical vein endothelial cell line ECV-304 and human kidney cell line 293T (Liver Cancer Institute, Fudan University, Shanghai, China) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum. Male BALB/c-nu/nu mice (4-6 weeks old, Slac Laboratory Animal, Shanghai, China) were kept in the animal facilities at the Nanjing Medical University and maintained under specific pathogen-free conditions. All animal procedures were conducted according to the guidelines approved by the China Association of Laboratory Animal Care.
Isolation and lentiviral transduction of hMSCs hMSCs were isolated from the bone marrow of normal individuals undergoing bone marrow harvest for allogeneic bone marrow transplantation after informed consent, as described previously (Studeny et al., 2004) . hMSCs isolated between the third and fourth passages were used in the experiments. The bicistronic lentiviral expression vector (pLV-PEDF), which included human PEDF cDNA, followed by an IRES (internal ribosomal entry site) coupled to GFP cDNA, has been described previously (Gao et al., 2009) . Briefly, the IRES-EGFP coding sequence contained in the plasmid pIRES2-EGFP (Clontech, Mountain View, CA, USA) was amplified by PCR and cloned into a HIV-1-based selfinactivating lentivirus vector pWPT-GFP (kindly provided by Dr D Trono, University of Geneva, Geneva, Switzerland) Figure 6 Administration of hMSCs-PEDF prolonged the survival of tumor-bearing mice. Ten days after tumor inoculation in the liver, mice were treated i.v. with PBS, hMSCs-GFP, hMSCs-PEDF or recombinant LV-PEDF (n ¼ 10 for each group). All mice were followed up daily and survival times were recorded. The log-rank test was used to assess the statistical significance of differences in survival among the groups. The survival time of mice treated with hMSCs-PEDF was significantly longer than that of PBS-treated group (*Po0.001).
replacing the existing GFP sequence. The resultant vector plasmid, pLV-GFP, was used as a control. The human PEDF cDNA derived from the expression plasmid pBLAST49-hPEDF (Invivogen, San Diego, CA, USA) was subcloned into the MluI site of the plasmid pLV-GFP to generate pLV-PEDF. Packaging of lentiviruses was performed using a transient cotransfection system (Kikuchi et al., 2004) . For lentiviral transduction of hMSCs, B5 Â 10 5 hMSCs were plated on 100-mm cell culture dishes and allowed to attach overnight. The medium was replaced with 5 ml fresh lentiviral supernatant (LV-PEDF or LV-GFP), and 8 mg/ml polybrene (Sigma, St Louis, MO, USA) to assist the uptake of viral particles. Either LV-PEDF-transduced hMSCs (hMSCs-PEDF) or LV-GFP-transduced hMSCs (hMSCs-GFP) were collected 48 h later. The number of GFP-positive cells determined by fluorescence-activated cell sorting analysis was used as a parameter to estimate the genetically modified cell fraction.
Western blot
To confirm the production and secretion of PEDF, hMSCs were infected with lentivirus and the medium was replaced with 10 ml serum-free a-minimum essential medium. After a further 48 h of incubation, the CM was collected. Both CM and 25 mg of each cell lysate were subjected to electrophoresis on a 12% SDS-polyacrylamide gel and electrotransferred onto a polyvinylidene fluoride membrane. The membrane was blocked with Tris-buffered saline containing 5% nonfat milk powder for 1 h and then incubated overnight with a mouse anti-human PEDF monoclonal antibody (Chemicon, Temecula, CA, USA) or a mouse anti-b-actin monoclonal antibody (MultiSciences, Hangzhou, China). The membrane was then incubated for 1 h with goat anti-mouse immunoglobulin G (Bio-Rad, Hercules, CA, USA). Immunoreactivity was detected using an enhanced chemiluminescence detection system (Pierce, Rockford, IL, USA).
In vitro tube formation assay To evaluate the antiangiogenic activity of PEDF produced by hMSCs-PEDF, an in vitro tube formation assay was performed as described previously (Ou-Yang et al., 2006) . Matrigel (50 ml; BD Biosciences, San Jose, CA, USA) was added to each well of a 96-well plate and allowed to polymerize. A suspension of 5 Â 10 3 ECV-304 cells was passed into a Matrigel-coated well. The cells were treated with the CM collected from hMSCs, hMSCs-GFP or hMSCs-PEDF cells. All assays were performed in triplicate. The cells were incubated for 24 h at 37 1C and viewed under a light microscope. Five fields were viewed, the tubes were counted and data were averaged.
In vitro migration assay The ability of hMSCs to migrate to hepatocarcinoma cells was measured using Boyden transwell chambers with 8-mm filter membranes (Corning, Acton, MA, USA). MHCC-97H, HepG2 or L02 cells were incubated in serum-free medium for 48 h, and the resulting CM was used as a chemoattractant. Either hMSCs or hMSCs-PEDF (5 Â 10 4 ) were resuspended in 200 ml of serum-free a-minimum essential medium containing 0.1% bovine serum albumin and loaded in the upper compartment. The lower compartment was filled with 600 ml of the CM. After incubation at 37 1C for 6 h, the nonmigrated cells were removed from the upper surface of the membrane using a cotton swab. Cells that had migrated to the lower surface were fixed with absolute methanol and stained with crystal violet. The number of cells that had migrated to the lower side of the filter was counted under a light microscope MSCs-based PEDF gene therapy for HCC Y Gao et al with five fields (magnification, Â 100). All experiments were conducted in triplicate.
Intrahepatic tumor model
An orthotopic metastatic HCC model was established according to the methods described by Lee et al. (2005) . Approximately 1 Â 10 7 MHCC-97H cells in 0.2 ml PBS were injected subcutaneously into the right flank of each mouse. Once the tumors reached 1 cm in diameter, they were removed and cut into 1.0-mm 3 pieces. One piece was then implanted into the left liver lobe of each mouse. Macroscopically detectable tumors developed within 10 days with an invasive growth pattern and displacement of normal liver tissue (data not shown).
In vivo migration assay hMSCs homing to the tumor sites in the liver in vivo was determined by labeling the cells with the fluorescent dye CM-DiI (Molecular Probes, Eugene, OR, USA) before in vivo administration according to the manufacturer's instructions. To assess the ability of hMSCs to migrate toward tumors, an MHCC-97H-GFP (MHCC-97H cells stably transduced with lentivirus LV-GFP) intrahepatic tumor model was established as described above. Ten days after tumor inoculation into the liver, 10 6 CM-DiI-labeled hMSCs resuspended in 200 ml PBS were injected into the mice through the mouse tail vein. On days 7 and 14 after hMSC injection, organs (such as the liver, spleen, lungs, heart, brain, pancreas and kidneys) were harvested and cryosectioned. Distribution of CM-DiI-labeled hMSCs was assessed by direct visualization using a fluorescence microscope.
In vivo efficacy experiments of hMSCs-PEDF Ten days after the implantation of MHCC-97H xenografts into the left liver lobes of the mice (as described above), the mice were divided into four treatment groups (n ¼ 22 for each group). Mice in each group were administered one of the following by tail vein injection: PBS (control group), 10 6 hMSCs-GFP, 10 6 hMSCs-PEDF or 10 9 TU of recombinant LV-PEDF. After 35 days of treatment, 12 randomly selected mice from each group were killed and autopsied. Their livers were removed and the volume of each primary liver tumor was calculated using the following formula: V ¼ a 2 Â b Â 0.52 (where a is the shortest diameter and b is the longest diameter). Liver tumor tissues and all animal lungs were fixed in 4% paraformaldehyde and embedded in paraffin for tissue sectioning. Pulmonary metastases were assessed by microscopic examination of hematoxylin and eosin-stained serial paraffin sections as described previously .
The remaining mice (n ¼ 10 for each group) were followed up daily, and their survival times were recorded.
ELISA for expression of human PEDF After administration of treatment, blood was collected from the mice on days 7, 14, 21, 28 and 35, and sera were stored frozen at À80 1C until use. Concentrations of human PEDF in sera and the CM were determined using a commercial PEDF ELISA kit (Chemicon) according to the manufacturer's instructions.
Immunohistochemistry
The degree of angiogenesis was determined by calculating the intratumoral microvessel density. Briefly, paraformaldehydefixed and paraffin-embedded sections were stained with rat anti-mouse CD34 monoclonal antibody (HyCult Biotechnology, Uden, The Netherlands) as a primary antibody and subsequently with biotin-conjugated goat anti-rat IgG (Pharmingen, San Diego, CA, USA) as a secondary antibody. Diaminobenzidine/hydrogen peroxidase (Dako, Carpinteria, CA, USA) was used as the chromogen substrate. All slides were counterstained with hematoxylin. The tissue sections were screened using a low-power field ( Â 40), and five areas with the most intense neovascularization (hotspots) were selected. Microvessel counts of these areas were performed using a high-power field ( Â 200). In all samples, the mean value of the number of microvessels was calculated from the five vascular hotspots.
Statistical analyses
All values were presented as mean ± s.e. Statistical significance was evaluated using the two-tailed Mann-Whitney U-test; Po0.05 was considered significant. Survival data were analyzed using the Kaplan-Meier plot, and their statistical significance was determined using the log-rank test.
